280 related articles for article (PubMed ID: 34948117)
1. Adult-Onset Still's Disease: Novel Biomarkers of Specific Subsets, Disease Activity, and Relapsing Forms.
Maranini B; Ciancio G; Govoni M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948117
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis and management of adult-onset Still's disease.
Efthimiou P; Georgy S
Semin Arthritis Rheum; 2006 Dec; 36(3):144-52. PubMed ID: 16949136
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis, disease course, and prognosis of adult-onset Still's disease: an update and review.
Wang MY; Jia JC; Yang CD; Hu QY
Chin Med J (Engl); 2019 Dec; 132(23):2856-2864. PubMed ID: 31856058
[TBL] [Abstract][Full Text] [Related]
4. The implication of interferon-γ-producing immunocompetent cells for evaluating disease activity and severity in adult-onset Still's disease.
Ichikawa T; Shimojima Y; Kishida D; Ueno KI; Sekijima Y
Int J Rheum Dis; 2021 Sep; 24(9):1176-1185. PubMed ID: 34241971
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Infection May Trigger Adult-Onset Still's Disease Onset or Relapses.
Jia J; Shi H; Liu M; Liu T; Gu J; Wan L; Teng J; Liu H; Cheng X; Ye J; Su Y; Sun Y; Gong W; Yang C; Hu Q
Front Immunol; 2019; 10():898. PubMed ID: 31068953
[TBL] [Abstract][Full Text] [Related]
6. Pyroptosis: the potential eye of the storm in adult-onset Still's disease.
He X; You R; Shi Y; Zeng Z; Tang B; Yu J; Xiao Y; Xiao R
Inflammopharmacology; 2023 Oct; 31(5):2269-2282. PubMed ID: 37429997
[TBL] [Abstract][Full Text] [Related]
7. Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.
Sfriso P; Bindoli S; Galozzi P
Drugs; 2018 Aug; 78(12):1187-1195. PubMed ID: 30069732
[TBL] [Abstract][Full Text] [Related]
8. Adult-onset Still's disease: Advances in the treatment.
Castañeda S; Blanco R; González-Gay MA
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):222-238. PubMed ID: 27886796
[TBL] [Abstract][Full Text] [Related]
9. A Case of Adult-Onset Still's Disease Treated with Monitoring of Serum Tacrolimus Levels.
Ohe M; Bohgaki T
Bull Hosp Jt Dis (2013); 2015 Jul; 73(3):213-6. PubMed ID: 26535602
[TBL] [Abstract][Full Text] [Related]
10. Adding colchicine to immunosuppressive treatments; a potential option for biologics-refractory adult-onset Still's disease.
Asano T; Furuya MY; Sato S; Kobayashi H; Watanabe H; Suzuki E; Migita K
BMC Res Notes; 2018 May; 11(1):320. PubMed ID: 29784018
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory adult onset Still's disease with tocilizumab-a single centre experience and literature review.
Reihl Crnogaj M; Čubelić D; Babić A; Mayer M; Anić B
Rheumatol Int; 2020 Aug; 40(8):1317-1325. PubMed ID: 32506202
[TBL] [Abstract][Full Text] [Related]
12. Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options.
Bindoli S; Baggio C; Doria A; Sfriso P
Drugs; 2024 Mar; 84(3):257-274. PubMed ID: 38441807
[TBL] [Abstract][Full Text] [Related]
13. TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still's Disease and Their Association with Disease Activity and Clinical Manifestations.
Kim HA; Han JH; Kim WJ; Noh HJ; An JM; Yim H; Jung JY; Kim YS; Suh CH
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27537874
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil-derived lipocalin-2 in adult-onset Still's disease: a novel biomarker of disease activity and liver damage.
Jia J; Yang L; Cao Z; Wang M; Ma Y; Ma X; Liu Q; Teng J; Shi H; Liu H; Cheng X; Ye J; Su Y; Sun Y; Chi H; Liu T; Wang Z; Wan L; Yang C; Hu Q
Rheumatology (Oxford); 2021 Jan; 60(1):304-315. PubMed ID: 32766690
[TBL] [Abstract][Full Text] [Related]
15. The Role of RIPK1/3 in Adult Onset Still's Disease Patients With Liver Damage: A Preliminary Study.
Liu X; Guo R; Meng X; Fang J; Lu L
Front Immunol; 2020; 11():560744. PubMed ID: 33329521
[TBL] [Abstract][Full Text] [Related]
16. Refractory Adult-onset Still's Disease Treated with a Combination of Methotrexate and Etanercept.
El Hasbani G; Ahmad Y; Cassetta M
Curr Rheumatol Rev; 2024; 20(2):219-222. PubMed ID: 37855287
[TBL] [Abstract][Full Text] [Related]
17. Current treatment options and safety considerations when treating adult-onset Still's disease.
Cavalli G; Farina N; Campochiaro C; Baldissera E; Dagna L
Expert Opin Drug Saf; 2020 Dec; 19(12):1549-1558. PubMed ID: 33078630
[TBL] [Abstract][Full Text] [Related]
18. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.
Kontzias A; Efthimiou P
Drugs; 2008; 68(3):319-37. PubMed ID: 18257609
[TBL] [Abstract][Full Text] [Related]
19. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease.
Chen DY; Lan JL; Lin FJ; Hsieh TY
J Rheumatol; 2004 Nov; 31(11):2189-98. PubMed ID: 15517632
[TBL] [Abstract][Full Text] [Related]
20. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.
Lenert A; Yao Q
Semin Arthritis Rheum; 2016 Jun; 45(6):711-6. PubMed ID: 26672682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
